Basis of Presentation and Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2023

Basis of Presentation and Summary of Significant Accounting Policies [Abstract]

Restricted Cash

The following table provides a reconciliation of the components of cash, cash equivalents and restricted cash reported in the Company’s consolidated balance sheets to the total of the amount presented in the consolidated statements of cash flows (in thousands):

	December 31,
	2023		2022
Cash and cash equivalents	$	6,784	$	5,434
Restricted cash		1,334		1,361
Total cash, cash equivalents and restricted cash presented in the consolidated statements of cash flows	$	8,118	$	6,795

Accrued Warranty Costs Activity

The activity in the warranty accrual during the years ended December 31, 2023 and 2022 is summarized as follows (in thousands):

	December 31,
	2023			2022
Balance, beginning of year	$	207		$	79
Additions		237			246
Expirations and claims satisfied		(141	)		(118	)
Total		303			207
Less current portion within accrued expenses and other current liabilities		(180	)		(136	)
Balance within deferred revenues and other liabilities	$	123		$	71

Disaggregation of Revenue

The following table presents the Company’s net revenues disaggregated by dermatology recurring procedures and dermatology procedures equipment (in thousands):

	Year Ended December 31,
	2023		2022
Dermatology recurring procedures	$	21,530	$	23,025
Dermatology procedures equipment		11,828		13,136
Total net revenues	$	33,358	$	36,161

Future Undiscounted Fixed Treatment Code Payments

The following table summarizes the Company’s expected future undiscounted fixed treatment code payments from international dermatology recurring procedures, the Company’s only long-term arrangements (in thousands):

Years ending December 31:
2024	$	1,319
2025		787
2026		569
2027		298
	$	2,973

Antidilutive Securities Excluded from Computation of Net Loss Per Share

The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:

	December 31,
	2023		2022
Stock options		7,728,721		4,474,714
Common stock warrants		800,000		373,626
Restricted stock units		22,654		278,004
		8,551,375		5,126,344